## Eileen M Barry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4945591/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs. Nature Microbiology, 2022, 7, 251-261.	13.3	23
2	Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design. Scientific Reports, 2021, 11, 2751.	3.3	23
3	Identification of an Attenuated Substrain of Francisella tularensis SCHU S4 by Phenotypic and Genotypic Analyses. Pathogens, 2021, 10, 638.	2.8	2
4	Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. Nature Communications, 2021, 12, 3696.	12.8	27
5	Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia. Pathogens, 2021, 10, 799.	2.8	2
6	Evaluation of a Live Attenuated S. sonnei Vaccine Strain in the Human Enteroid Model. Pathogens, 2021, 10, 1079.	2.8	5
7	Sequence variations in the ETEC CS6 operon affect transcript and protein expression. Virulence, 2021, 12, 2659-2669.	4.4	2
8	The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection. Pathogens, 2021, 10, 1646.	2.8	5
9	Research in a time of enteroids and organoids: how the human gut model has transformed the study of enteric bacterial pathogens. Gut Microbes, 2020, 12, 1795389.	9.8	26
10	Characterization of Schu S4 <i>aro</i> mutants as live attenuated tularemia vaccine candidates. Virulence, 2020, 11, 283-294.	4.4	7
11	A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice. Npj Vaccines, 2020, 5, 30.	6.0	20
12	Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine, 2019, 37, 4768-4774.	3.8	28
13	Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing Enterotoxigenic Escherichia coli Strain TW11681. Pathogens, 2019, 8, 84.	2.8	11
14	A new human challenge model for testing heat-stable toxin-based vaccine candidates for enterotoxigenic Escherichia coli diarrhea – dose optimization, clinical outcomes, and CD4+ T cell responses. PLoS Neglected Tropical Diseases, 2019, 13, e0007823.	3.0	15
15	A tale of two bacterial enteropathogens and one multivalent vaccine. Cellular Microbiology, 2019, 21, e13067.	2.1	16
16	A roadmap for enterotoxigenicEscherichia colivaccine development based on volunteer challenge studies. Human Vaccines and Immunotherapeutics, 2019, 15, 1357-1378.	3.3	20
17	Genome and Functional Characterization of Colonization Factor Antigen I- and CS6-Encoding Heat-Stable Enterotoxin-Only Enterotoxigenic Escherichia coli Reveals Lineage and Geographic Variation. MSystems, 2019, 4, .	3.8	25
18	Evaluating Shigella flexneri Pathogenesis in the Human Enteroid Model. Infection and Immunity, 2019, 87	2.2	71

EILEEN M BARRY

#	Article	IF	CITATIONS
19	Biochemical and Immunological Evaluation of Recombinant CS6-Derived Subunit Enterotoxigenic Escherichia coli Vaccine Candidates. Infection and Immunity, 2019, 87, .	2.2	15
20	Deletion of the Major Facilitator Superfamily Transporter fptB Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis. Infection and Immunity, 2018, 86, .	2.2	6
21	Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis. PLoS ONE, 2018, 13, e0205928.	2.5	10
22	A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge. MSphere, 2018, 3, .	2.9	27
23	Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection. Infection and Immunity, 2018, 86, .	2.2	18
24	Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity. Vaccine Journal, 2017, 24, .	3.1	11
25	Analysis of Shigella flexneri Resistance, Biofilm Formation, and Transcriptional Profile in Response to Bile Salts. Infection and Immunity, 2017, 85, .	2.2	65
26	Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products. Vaccine Journal, 2017, 24, .	3.1	21
27	Differential Growth of Francisella tularensis, Which Alters Expression of Virulence Factors, Dominant Antigens, and Surface-Carbohydrate Synthases, Governs the Apparent Virulence of Ft SchuS4 to Immunized Animals. Frontiers in Microbiology, 2017, 8, 1158.	3.5	32
28	Characterization of a multicomponent live, attenuated <i>Shigella flexneri</i> vaccine. Pathogens and Disease, 2016, 74, ftw034.	2.0	15
29	The synthesis of OspD3 (ShET2) in <i>Shigella flexneri</i> is independent of OspC1. Gut Microbes, 2016, 7, 486-502.	9.8	14
30	Genomic diversity of EPEC associated with clinical presentations of differing severity. Nature Microbiology, 2016, 1, 15014.	13.3	66
31	Simple method for purification of enterotoxigenic Escherichia coli fimbriae. Protein Expression and Purification, 2016, 119, 130-135.	1.3	4
32	Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates. Pathogens and Disease, 2015, 73, ftv036.	2.0	15
33	Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development. Clinical Infectious Diseases, 2014, 59, 933-941.	5.8	297
34	Gut-Homing Conventional Plasmablasts and CD27− Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. Frontiers in Immunology, 2014, 5, 374.	4.8	21
35	Live Attenuated Mutants of Francisella tularensis Protect Rabbits against Aerosol Challenge with a Virulent Type A Strain. Infection and Immunity, 2014, 82, 2098-2105.	2.2	32
36	Progress and pitfalls in Shigella vaccine research. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 245-255.	17.8	117

EILEEN M BARRY

0

#	Article	IF	CITATIONS
37	Formulation and Stabilization of Francisella tularensis Live Vaccine Strain. Journal of Pharmaceutical Sciences, 2011, 100, 3076-3087.	3.3	28
38	Live Attenuated Shigella dysenteriae Type 1 Vaccine Strains Overexpressing Shiga Toxin B Subunit. Infection and Immunity, 2011, 79, 4912-4922.	2.2	28
39	Vaccines against Tularemia. Hum Vaccin, 2009, 5, 832-838.	2.4	33
40	Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine, 2009, 27, 2426-2436.	3.8	40
41	Safety and Immunogenicity of CVD 1208S, a Live, Oral <i>î"guaBA î"sen î"set Shigella flexneri</i> 2a Vaccine Grown on Animal-Free Media. Hum Vaccin, 2007, 3, 268-275.	2.4	72
42	Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology, 2007, 5, 540-553.	28.6	303
43	Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208. Journal of Infectious Diseases, 2004, 190, 1745-1754.	4.0	86
44	Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine, 2003, 21, 333-340.	3.8	58
45	Genetic Characterization and Immunogenicity of Coli Surface Antigen 4 from Enterotoxigenic Escherichia coli when It Is Expressed in a Shigella Live-Vector Strain. Infection and Immunity, 2003, 71, 1352-1360.	2.2	28

Live Attenuated Vectors: Have they Delivered?. , 0, , 72-86.